Lugei Foundation Uganda

Email

info@lugeifoundation.org

Phone

+256788880404

Web

www.lugeifoundation.org

Address

Uganda
About Lugei Foundation Uganda

Lugei Foundation Is a registered Nonprofit organization in Uganda. It aims at improving lives of marginalized and most vulnerable populations through integrated and community driven solutions based on scientific evidence, innovation, creativity and multidisciplinary partnerships in a compassionate environment. This is done through linking health service providers, health consumers and key stakeholders such as government and other civil societies such as national organization of people living with hepatitis B in Uganda (NOLPHB) , hepatitis AIDS organization and great lakes peace center to improve access and quality 0f hepatitis care through training , education
research and advocacy clinical and preventive interventions such as health promotion services through lugei health centre project and the social media platforms such as Facebook, lugei foundation watsup hepatitis advocacy platform, Twitter handle, Instagram platforms and Tiktok platforms targeting vulnerable communities and the general population. A community oriented primary care model (COPC) model and the point of care facility approach are the critical intervention approaches used.
Uganda is highly endemic for viral hepatitis B and C with a prevalence of 4.1% for Hepatitis B among Adults aged 15 to 64 years in a survey by the Uganda population based HIV impact assessment (UPHIA) and estimate of 1% to 2% with no study done.
The UPHIA survey further indicates that chronic hepatitis B infection prevalence varies across the country with the highest rates in Northern region with 4.6% , in Mid-North 4.4% North-East 4.4% West Nile- 3.8% where most of our hepatitis activities are currently running including supporting one of the viral hepatitis B clinic at the District General Hospital koboko. East Central – 2.7%, Mid- East 2.1% Central 2.0% kampala 1.9% ( our head office is located) , Mid- west 1.8% , Central 1.6% and the lowest in southwest at 0.8%
Our hepatitis activities are aligned to the ministry of Health Uganda guidelines and the national hepatitis strategic plan , the hepatitis Control activities include: testing and screening of the general population and the communities around using a model of outreaches and facility based approach, advocacy and community sensitization, Awareness raising and commemoration 0f the world Hepatitis Day every 28th July of every year, technical support supervision through ministry of Health spaces, linkage to care of whose who tested positive, Hepatitis vaccination and mass campaigns involvement, Hepatitis training, mentorship and member of the national technical working group viral hepatitis in Uganda
The foundation is currently supporting the Hepatitis B clinic at Koboko General Hospital and continues to run the Annual Hepatitis Medical camp in Koboko District in Uganda that targets urban settled south sudanese refugees and Congolese refugees in Koboko, Maracha and Yumbe Districts.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close